Mr. Thomas joined Orchard Therapeutics, a biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, as its Chief Financial Officer and Chief Business Officer in January 2018. Previously, Mr. Thomas served as the President and Chief Operating Officer of AMAG Pharmaceuticals, Inc. from 2015 to April 2017, and previously served as AMAG’s Executive Vice President and Chief Operating Officer from 2012 through 2015 and Executive Vice President, Chief Financial Officer and Treasurer from 2011 through 2012. Prior to joining AMAG, he served as Senior Vice President, Chief Operating Officer and Chief Financial Officer for Molecular Biometrics, Inc., a commercial stage medical diagnostics company, from 2008 to 2011. Prior to Molecular Biometrics, Mr. Thomas spent four years at Critical Therapeutics, Inc., a public biopharmaceutical company, from 2004 to 2008, where he was promoted to President in 2006 and Chief Executive Officer in 2006 from the position of Senior Vice President and Chief Financial Officer. He also served on the Board of Directors of Critical Therapeutics from 2006 to 2008. Prior to 2004, Mr. Thomas served as the Chief Financial Officer and Vice President of Finance and Investor Relations at Esperion Therapeutics, Inc., a public biopharmaceutical company. Mr. Thomas was a member of the Board of Directors of the Massachusetts Biotechnology Council from 2007 to 2015. In July 2017, Mr. Thomas was appointed to the Board of Directors at Spero Therapeutics, in this role he will also serve as the Chair of the Audit Committee. Mr. Thomas holds a B.B.A. from the University of Michigan, Ann Arbor.